Myeloid neoplasms after chemotherapy and PRRT: myth and reality

被引：30

作者：

Bodei, Lisa ^{[1
,2
]}

Modlin, Irvin M. ^{[2
,3
]}

Luster, Markus ^{[4
]}

Forrer, Flavio ^{[5
]}

Cremonesi, Marta ^{[6
]}

Hicks, Rodney J. ^{[7
]}

Ezziddin, Samer ^{[8
]}

Kidd, Mark ^{[9
]}

Chiti, Arturo ^{[10
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10021 USA

[2] LuGenIum Consortium Independent Res, London, England

[3] Yale Univ, Sch Med, Gastroenterol Surg, New Haven, CT USA

[4] Univ Hosp Marburg, Dept Nucl Med, Marburg, Germany

[5] Cantonal Hosp, Nucl Med, St Gallen, Switzerland

[6] European Inst Oncol, Div Hlth Phys, Milan, Italy

[7] Peter MacCallum Canc Ctr, Ctr Canc Imaging, St Andrews Pl, Melbourne, Vic, Australia

[8] Saarland Univ Hosp, Dept Nucl Med, Homburg, Saarland, Germany

[9] Wren Labs, Branford, CT USA

[10] Humanitas Univ, Milan, Italy

来源：

关键词：

myeloid neoplasms; alkylating chemotherapy; PRRT; neuroendocrine tumors; RECEPTOR RADIONUCLIDE THERAPY; 2ND PRIMARY MALIGNANCIES; MYELODYSPLASTIC SYNDROMES; NEUROENDOCRINE TUMORS; THYROID-CANCER; RADIOIODINE TREATMENT; ACUTE-LEUKEMIA; UNITED-STATES; DNA-DAMAGE; PHASE-II;

D O I：

10.1530/ERC-16-0258

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Peptide receptor radionuclide therapy (PRRT) with Y-90-octreotide or Lu-177-octreotate is an effective treatment for inoperable or metastatic neuroendocrine tumors (NETs), particularly well-differentiated gastroenteropancreatic or bronchopulmonary NETs. PRRT is generally extremely well tolerated, with modest toxicity to target organs, kidney and bone marrow. Nevertheless, a priori concerns regarding long-term effects lead clinicians such as Brieau and coworkers, in this ERC issue, to ascribe to the combination of alkylating agents and PRRT the apparently high occurrence (n = 4) of myeloproliferative events (therapy-related myeloid neoplasms (t-MNs)) in a small cohort of 20 progressive, advanced digestive NETs treated with PRRT after chemotherapy. Anecdotal reports of myelotoxic events should be placed in the correct perspective of larger series, where the reported incidence of these events is similar to 2%, with the aim of promoting a balanced awareness of the issue and unbiased and reasonable overall conclusions. For a comprehensive definition of the issue, we provide an evaluation of the occurrence of t-MN in patients treated with various myelotoxic treatments.

引用

页码：C1 / C7

页数：7

共 51 条

[1]

Bernard BF, 1997, J NUCL MED, V38, P1929

[2] Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion:: a phase I study [J].

Bodei, L ;

Cremonesi, M ;

Zoboli, S ;

Grana, C ;

Bartolomei, M ;

Rocca, P ;

Caracciolo, M ;

Mäcke, HR ;

Chinol, M ;

Paganelli, G .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (02) :207-216

[3] Peptide receptor therapies in neuroendocrine tumors [J].

Bodei, L. ;

Ferone, D. ;

Grana, C. M. ;

Cremonesi, M. ;

Signore, A. ;

Dierckx, R. A. ;

Paganelli, G. .

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2009, 32 (04) :360-369

[4] Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer [J].

Bodei, Lisa ;

Kwekkeboom, Dik J. ;

Kidd, Mark ;

Modlin, Irvin M. ;

Krenning, Eric P. .

SEMINARS IN NUCLEAR MEDICINE, 2016, 46 (03) :225-238

[5] Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors [J].

Bodei, Lisa ;

Kidd, Mark ;

Paganelli, Giovanni ;

Grana, Chiara M. ;

Drozdov, Ignat ;

Cremonesi, Marta ;

Lepensky, Christopher ;

Kwekkeboom, Dik J. ;

Baum, Richard P. ;

Krenning, Eric P. ;

Modlin, Irvin M. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (01) :5-19

[6] Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome [J].

Boehrer, S. ;

Ades, L. ;

Tajeddine, N. ;

Hofmann, W. K. ;

Kriener, S. ;

Bug, G. ;

Ottmann, O. G. ;

Ruthardt, M. ;

Galluzzi, L. ;

Fouassier, C. ;

Tailler, M. ;

Olaussen, K. A. ;

Gardin, C. ;

Eclache, V. ;

de Botton, S. ;

Thepot, S. ;

Fenaux, P. ;

Kroemer, G. .

ONCOGENE, 2009, 28 (22) :2205-2218

[7] Genetic and epigenetic features in radiation sensitivity - Part I: Cell signalling in radiation response [J].

Bourguignon, MH ;

Gisone, PA ;

Perez, MR ;

Michelin, S ;

Dubner, D ;

Di Giorgio, M ;

Carosella, ED .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (02) :229-246

[8] High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy [J].

Brieau, Bertrand ;

Hentic, Olivia ;

Lebtahi, Rachida ;

Palazzo, Maxime ;

Ben Reguiga, Makrem ;

Rebours, Vinciane ;

Maire, Frederique ;

Hammel, Pascal ;

Ruszniewski, Philippe ;

Fenaux, Pierre .

[9] The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer [J].

Brown, Aaron. P. ;

Chen, Jergin ;

Hitchcock, Ying J. ;

Szabo, Aniko ;

Shrieve, Dennis C. ;

Tward, Jonathan. D. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (02) :504-515

[10] Therapy-Related Myeloid Neoplasms [J].

Bueso-Ramos, Carlos E. ;

Kanagal-Shamanna, Rashmi ;

Routbort, Mark J. ;

Hanson, Curtis A. .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2015, 144 (02) :207-218

← 1 2 3 4 5 6 →